Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
The dysregulation of immune cells induced by uric acid: mechanisms of inflammation associated with hyperuricemia and its complications
00:22:57 Craig Williams I mean, metformin doesnt, you know, fix the diabetes
Evaluating rezatapopt*, a first-in-class p53 reactivator, as a treatment for TP53 Y220Cmutant locally advanced and metastatic solid tumours The experts discuss: TP53 Y220C mutation and rationale for targeted therapy Study overview and practice implications, spotlighting ovarian cancer Testing strategies for early and accurate patient identification Video in this post *Rezatapopt is an investigational agent which is not approved by a regulatory agency This programme has been sponsored by PMV Pharma #MedicalEducation #Oncology Update from AACRNCIEORTC 2025: PYNNACLE Phase 2 evaluating rezatapopt in TP53 Y220Cmutant solid tumours To view or add a comment, sign in 26,256 followers
Card Fail Rev 10:e14
